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Abstract
Background: This study aimed to evaluate the levels of  thyroid hormones and lactate dehydrogenase (LDH) isoenzymes in 
obese and/or diabetic patients. 
Subjects and methods: Forty male subjects categorized into four equal groups; group 1: Non obese control subjects, group 
2: Subjects suffering from type 2 diabetes mellitus (T2DM), group 3:   Obese subjects (BMI ≥ 30 kg/m2) and group 4: Subjects 
thatwere obese and had type 2 diabetes mellitus (T2DM). Liver, kidney, lipid, thyroid hormones, total LDH and LDH isoen-
zymes levels were determined. 
Results: There was a significant increase of  TSH level  (p<0.001) in diabetic group as compared with control group and a highly 
significant increase of  TSH was obtained in obese and obese diabetic groups versus control and diabetic patients. LDH 2 was 
also highly significantly decreased in obese and obese diabetic groups versus diabetic patients. Percentage of  LDH 4 was signifi-
cantly decreased in both diabetic and obese groups and not significantly changed in obese diabetic patients as compared with 
the control group. LDH 5 percentage showed very highly significant decrease in diabetic, obese and highly significant decrease 
in obese diabetic groups when compared with control subjects while it was not significantly changed in obese and obese diabetic 
groups as compared with diabetic patients. 
Conclusion: LDH isozymes can be used as valuable diagnostic markers for metabolic syndrome. This may help to explore the 
metabolic changes associated with obesity and diabetes complication and following up the complication of  these abnormalities.
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Diabetes mellitus, often simply referred to as diabetes, is 
a group of  metabolic diseases in which a person has high 
blood sugar, either because the body does not produce 
enough insulin, or because cells do not respond to the 
insulin that is produced. This high blood sugar produces 
the classical symptoms of  polyuria (frequent urination), 
polydipsia (increased thirst) and polyphagia (increased 
hunger). The most common forms of  diabetes are type 
1 diabetes (5%), an autoimmune disorder, and type 2 di-
abetes (95%) which is commonly associated with obesi-
ty. New criteria for diagnosis of  Diabetes mellitus type 
2 (T2DM) were published in 1998. These criteria were 
recommended by the American Diabetes Association 
(ADA) and the World Health Organization (WHO). In 
these recommendations, obesity ≥ 20% over desired 
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body weight or body mass index (BMI ≥ 27 kg/m2 was 
one of  the major risk factors for diabetes mellitus1. In 
healthy individuals, excess fat is stored in adipocytes and 
only low amounts of  triglycerides are maintained in non- 
adipocytes. In obese individuals, the capacity for adipose 
tissue to accommodate excess lipids can be exceeded, re-
sulting in the abnormal accumulation of  lipids in other 
tissues. Elevated cellular triglyceride content in muscle, 
liver and pancreatic islets is associated with physiological 
dysfunction (lipotoxicity) in those tissues and might be a 
primary contributing factor for the development of  obe-
sity related type 2 diabetes mellitus (T2DM)2.
Patients suffering from diabetes mellitus either type 1 
(IDDM) or type 2 (NIDDM) are at high risk for diseases 
whose etiology is related to various factors such as meta-
bolic abnormalities and its enzymes such as lactate Dehy-
drogenase (LDH)4. LDH is an enzyme that catalyzes the 
conversion of  lactate to Pyruvate; an important step in 
energy production in cells. Some of  the organs relative-
ly rich in LDH are the heart, kidney, liver, and muscles3. 
Because this enzyme is actually composed of  five differ-
ent isoenzymes, however, analysis of  the different LDH 
isoenzyme levels in the blood can help in the diagnosis 
of  some diseases. The five LDH isoenzymes are: LDH-1, 
LDH-2, LDH-3, LDH-4, and LDH-5. In general, each 
isoenzyme is used mostly by the cells in a specific tissue. 
LDH-1 is found mainly in the heart. LDH-2 is primar-
ily associated with the system in the body that defends 
against infection (reticuloendothelial system). LDH-3 is 
found in the lungs and other tissues, LDH-4 in the kid-
ney, placenta, and pancreas, and LDH-5 in liver and striat-
ed (skeletal) muscle. Normally, levels of  LDH-2 are high-
er than those of  the other isoenzymes4.
Certain diseases have classic patterns of  elevated LDH 
isoenzyme levels. For example, an LDH-1 level higher 
than that of  LDH-2 is indicative of  a heart attack or inju-
ry; elevations of  LDH-2 and LDH-3 indicate lung injury 
or disease; elevations of  LDH-4 and LDH-5 indicate liver 
or muscle disease or both. A rise of  all LDH isoenzymes 
at the same time is diagnostic of  injury to multiple or-
gans. For example, a heart attack with congestive heart 
failure may cause symptoms of  lung and liver congestion. 
Advanced cancer and autoimmune diseases such as lupus 
can also cause this pattern5. In addition, one of  the most 
important diagnostic uses for the LDH isoenzymes test 
is in the differential diagnosis of  myocardial infarction or 
heart attack. The total LDH level rises within 24-48 hours 
after a heart attack, peaks in two to three days, and returns 
to normal in approximately five to ten days. This pattern 
is a useful tool for a delayed diagnosis of  heart attack6.
         
This study aimed to determine the different levels of  
some biochemical parameters that are closely related to 
the problems of  human diabetes and obesity. In addition, 
it aimed to find out the possibility of  using lactate De-
hydrogenase (LDH) isoenzymes in case of  obese and/
or diabetic patients as biomarkers. It was also designed 
to correlate between the levels of  LDH isoenzymes and 
other energy-related metabolites that are commonly 




This study was approved by the ethics committee of  the 
King Fahad Armed Forces Hospital, Jeddah, Saudi Ara-
bia for sample collection. Written informed consent was 
obtained from all participants prior to the study. The par-
ticipants completed an investigator-developed question-
naire on health history. Various demographic variables 
were assessed, including age in years, history of  diabetes, 
medication and physical activity. All were classified by 
yes/no based on self-report. The following criteria were 
established to identify subjects for this investigation.
• Self  – identify as Saudis’ men.
• 28 – 49 years age.
• Fasting glucose level from 80 to 110 mg/dl for the nor-
mal category and a glucose level ≥ 200 mg/dl for diabetic 
category.
• Body mass index (BMI) of  18.5 to 24.9 kg/m2 for the 
normal weight category and a BMI ≥ 30 kg/m2 for obese 
category.
Study design
This study was conducted on forty male subjects admitted 
to a clinical laboratory of  the King Fahad Armed Forces 
Hospital and diagnosed by professional physicians. Sam-
ples were categorized into four equal groups according to 
case history and clinical examination as follows: 
Group 1:  Non obese-non diabetic control subjects that 
were not suffering from any pathological condition (BMI 
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≤ 21.6  kg/m2). Group 2: Subjects that are suffering from 
diabetes mellitus type 2 (DM 2). Group 3: Subjects that 
from obesity (BMI ≥ 30 kg/m2). Group 4: Subjects that 
were obese and had type 2 diabetes mellitus.
Anthropometric assessment
Height and weight measurement were obtained from each 
participant by the same investigator. Subjects were re-
quired to remove shoes and heavy outer garments before 
the measurements of  height and weight. Body Mass In-
dex (BMI) was calculated by the equation BMI = Weight 
in kg/height in m2 as mentioned7.
Sample collection
After 10-12 hours of  overnight fasting, about five milli-
liters of  blood were drawn from each participant by us-
ing standard vein puncture technique in plain vaccutainer 
tubes for serum separation. The tubes were left at room 
temperature for about 30 minutes for blood clotting. The 
serum was separated by centrifugation at 2000 rpm for 10 
minutes. The serum was stored at -20oC till analysis.
Biochemical analysis
Determination of  Serum Glucose Level
GLU reagent (Siemens kit No. DF39A), when used in 
conjunction with The Dimension® X pand plus integrat-
ed chemistry system, is intended for quantitative deter-
mination of  glucose concentration in human serum ac-
cording to8.
Determination of  Serum total activity of  Lactate 
Dehydrogenase
The LDH (lactate dehydrogenase) determination meth-
od (Siemens kit No. DF54)  uses as a substrate L-lactate 
buffered at a pH of  9.4. Lactate dehydrogenase oxidizes 
the substrate in the presence of  NAD+ to yield pyru-
vate and NADH which absorbs colour at 340 nm. Lactate 
dehydrogenase activity is measured as a rate reaction at 
340/700 nm, proportional to the amount of  lactate dehy-
drogenase in the sample. 
Determination of  serum lipid profile
Cholesterol reagent (Siemens kit No. DF27), when used in 
conjunction with The Dimension® X pand plus integrat-
ed chemistry system, is intended for quantitative deter-
mination of  cholesterol concentration in human serum8. 
Quantitative determination of  HDL cholesterol (HDL-c) 
in serum was done according to the time end point meth-
ods9, by using Siemens kit No. DF48B. The method for 
LDL determination is in a two reagent format and de-
pends on the properties of  detergent 1, which solubilizes 
only non- LDL particles in Siemens kit No. DF131A9. 
The triglycerides determination method is based on an 
enzymatic procedure10, using Siemens kit No. DF69.
Determination of  serum kidney function tests
Blood urea nitrogen (BUN) was determined by using Sie-
mens kit No. DF21 based on the bichromatic (340, 383 
nm) rate technique11.   
In the presence of  a strong base such as NaOH, picrate 
reacts with creatinine to form a red chromophore (Sie-
mens kit No. DF33A). The rate of  increasing absorbance 
at 510 nm due to the formation of  this chromophore is 
directly proportional to the creatinine concentration in 
the sample and is measured using a bichromatic (510, 600 
nm) rate technique12.
Determination of  serum liver function tests
Alanine aminotransferase (ALT) and Aspartate amino-
transferase (AST) activities were determined using a bi-
chromatic (340, 700 nm) rate technique13.
Evaluation of  thyroid function profile
The architect TSH, FT3 and FT4 assay is a Chemilu-
minescent Microparticle Immunoassay (CMIA) for the 
quantitative determination of  human thyroid stimulating 
hormone, Free Triiodothyronine and Free Thyroxine in 
human serum. Evaluation and calculation of  the concen-
tration of  the antigen are carried out by means of  calibra-
tion curve that was established using standards of  known 
antigen concentration14.     
Electrophoretic pattern of  lactate Dehydrogenase 
Isoenzymes
Identification of  the LDH isoenzymes performed by 
electrophoresis depends on fluorescence of  NADH pro-
duced by the enzyme15. At the pH used (8.6 at 20oC), en-
zymes LDH-1 to LDH-4 migrate towards the anode and 
LDH-5 moves towards the cathode on the agarose film. 
The LDH isoenzymes are detected after a short incuba-
tion with a liquid overlay containing L-lactate and NAD. 
The reaction produces NADH, which fluoresces at al-
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kaline pH after excitation by light at about 360 nm. The 
isoenzymes are quantified by the relative proportion of  
fluorescence generated by each isoenzyme band.
Statistical analysis 
Statistical analyses were performed by using the Sta-
tistical Package for Social Sciences (SPSS) version 20.0 
(SPSS Inc., Chicago, IL, USA). Categorical variables were 
presented as frequencies. Independent samples T-test 
was used to compare between continuous variable and 
groups. The P value at < 0.05 was considered as signif-
icant. Persons correlation was determined between each 
single parameter and others.
Results
Table (1) showed that there were no significant chang-
es in the levels of  serum urea and creatinine in diabet-
ic, obese and obese diabetic groups as compared with 
the control group. In addition, there were no significant 
changes in these parameters found between obese and 
diabetic obese versus diabetic patients. However, serum 
ALT activity was significantly elevated in obese (P ≤ 0.01) 
and obese diabetic (P ≤ 0.01) groups when compared 
with control subjects. In addition, there was a significant 
increase in ALT activity of  obese (P ≤ 0.05) and obese 
diabetic (P ≤ 0.05) groups versus diabetic patients. On 
the other hand, serum AST activity was not significantly 
changed in all groups. 
Table 1. Serum kidney and liver function tests in different groups 
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Urea ( mg/dl ) 
















17.18 ±  2.7 
N.S 
N.S 
Creatinine (mg/dl ) 
















0.90 ± 0.2 
N.S 
N.S 
ALT ( U/L ) 




































22.27 ± 2.5 
N.S 
N.S 
P value: diabetic, obese and obese diabetic versus control group 
P*: obese and obese diabetic versus diabetic group 
N.S: Non Significant, P < 0.05: Significant, P< 0.01: Highly significant 
Table (2) demonstrated a significant increase in the mean 
serum level of  triglycerides in diabetic (P ≤ 0.05), obese 
(P ≤ 0.01) and obese diabetic (P ≤ 0.001) groups when 
compared with the control group. Triglycerides level of  
obese diabetic (P ≤ 0.05) and obese (P ≤ 0.05) subjects 
was also significantly elevated versus diabetic patients. 
The changes of  mean level of  total cholesterol, HDL-c 
and LDL-c were not significant in diabetic, obese and 
diabetic obese groups when compared with the control 
normal group and also there were no significant changes 
when compared with diabetic patients.
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Table 2. Serum lipid parameters in different groups 
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199.27 ± 23.6 
N.S 
N.S 
HDL- c (mg/dl ) 
















39.27 ± 8.4 
N.S 
N.S 
LDL- c (mg/dl) 
















130.36 ± 16.1 
N.S 
N.S 
P value: diabetic, obese and obese diabetic versus control group 
P*: obese and obese diabetic versus diabetic group 
N.S: Non Significant, P < 0.05: Significant, P< 0.01: Highly significant 
Table (3) showed the averages of  selected thyroid hor-
mones level in different groups under study. There was a 
significant increase of  TSH level in diabetic group (P ≤ 
0.05) as compared with control subjects and very high-
ly significant increase of  TSH in obese (P ≤ 0.001) and 
obese diabetic (P ≤ 0.001) groups versus control and di-
abetic patients. On the other hand, the changes of  FT3 
level were not significant in all groups when compared 
with control subjects and diabetic patients. In addition, 
FT4 levels showed different significant changes in obese 
and diabetic obese groups when compared with control 
and diabetic subjects.There was a highly significant in-
crease of  FT4 in diabetic subjects (P ≤ 0.01) versus the 
control group while there was a highly significant de-
crease in obese (P ≤ 0.01) and obese diabetic (P ≤ 0.01) 
groups versus diabetic patients.           
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Table 3. Serum thyroid hormones (TSH, FT3 and FT4) in studied groups 
 

































































14.27 ± 3.6 
N.S 
< 0.01  
  
14.06 ± 2.5 
N.S 
< 0.01 
P value: diabetic, obese and obese diabetic versus control group 
P*: obese and obese diabetic versus diabetic group 
N.S: Non Significant, P < 0.05: Significant, P< 0.01: Highly significant, P< 0.001: Very highly  
significant 
Results of  the present study listed in table (4) revealed 
that serum glucose level in diabetic (P ≤ 0.001) and obese 
diabetic (P ≤ 0.001) groups was very significantly high-
er than that in control subjects and in obese ones when 
compared with diabetic patients. On the other hand, there 
were no significant changes in both lactic acid and LDH 
activity in different groups as compared with control and 
diabetes subjects.
Table 4. Serum levels of Glucose, Lactate and Total Lactate  
Dehydrogenase activity in different experimental groups 
 




























220.27 ± 74.5 
< 0.001 
N.S 
Lactic Acid (mmol/L) 




































186.36 ± 29.5 
N.S 
N.S 
P value: Diabetic, obese and obese diabetic versus control group 
P*: Obese and obese diabetic versus diabetic group 
N.S: Non Significant, P< 0.001: Very highly significant 
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The percentage of  different LDH isoenzymes level ob-
tained for variable groups (table 5) showed between sig-
nificant and non-significant changes as described in the 
following details: Percentage of  LDH 1 was significantly 
decreased in diabetic (P ≤ 0.01), obese (P ≤ 0.01) and 
obese diabetic (P ≤ 0.01) groups as compared with con-
trol subjects, also there was a significant decrease in obese 
(P ≤ 0.01) and obese diabetic (P ≤ 0.01) groups versus 
diabetic patients.
LDH 2 percentage was significantly decreased in diabetic 
group (P ≤ 0.05), highly significantly decreased in both 
obese (P ≤ 0.01) and obese diabetic (P ≤ 0.01) groups 
when compared with the control one. LDH 2 was also 
highly significantly decreased in obese (P ≤ 0.01) and 
obese diabetic (P ≤ 0.01) groups versus diabetic patients. 
LDH3 mean percentage was not significantly changed in 
diabetic, obese and obese diabetic groups as compared 
with the control one and also not significantly changed in 
obese  and obese diabetic groups  versus diabetic patients.
Percentage of  LDH 4 was significantly decreased in 
both diabetic (P ≤ 0.05) and obese (P ≤ 0.01) groups 
and did not significantly change in obese diabetic patients 
as compared with the control group. The obese diabet-
ic LDH4 percent was significantly increased (P ≤ 0.01) 
while the obese group LDH4 percentage was not signifi-
cantly changed as in diabetic patients. LDH 5 percentage 
showed very highly significant decrease (P ≤ 0.001) in di-
abetic, obese (P ≤ 0.001) and highly significant decrease 
in obese diabetic (P ≤ 0.01) groups when compared with 
control subjects while it was not significantly changed in 
obese and obese diabetic groups as compared with dia-
betic patients. 
Table 5. Percentage of serum LDH Isoenzymes in different groups 
 











LDH 1 (%) 
















21.58  ±  1.8 
< 0.01 
< 0.01 
LDH 2 (%) 
















31.58  ± 1.8 
< 0.01  
< 0.01 
LDH 3 (%) 
















23.88  ± 1.9 
N.S 
N.S 
LDH 4 (%) 
















10.63 ± 1.5 
N.S 
< 0.01 
LDH 5 (%) 
















7.50 ± 0.2 
< 0.01 
N.S 
P value: diabetic, obese and obese diabetic versus control group 
P*: obese and obese diabetic versus diabetic group 
N.S: Non Significant, P < 0.05: Significant, P< 0.01: Highly significant,  
P< 0.001: Very highly significant 
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Discussion
This study was designed to find out the possibility of  us-
ing lactate dehydrogenase (LDH) isoenzymes as biomark-
ers in case of  obese and/or diabetic patients and to cor-
relate between the levels of  LDH isoenzymes and other 
energy-related metabolites in these patients. The impor-
tance of  continuous studying of  diabetes is a must where 
the incidence of  T2DM has been increasing rapidly in the 
past 2 decades and is expected to increase further16. It was 
estimated that the number of  adults with diabetes will be 
more than double from an estimated 143 million in 1997 
to 300 million by 202517. T2DM is accompanied notably 
by a high prevalence of  associated disorders; such as hy-
pertension; atherogenesis; metabolic syndrome; myocar-
dial infarction (MI); retinopathy (Rt); nephropathy (Np); 
neuropathy (Nu); vascular diseases (cardiac; cerebral and 
peripheral); and cardiovascular disease (CVD); which lead 
to significantly high morbidity and mortality18.
According to International Obesity Task Force (IOTF); 
Greece showed the highest prevalence of  both over-
weight and obese women (74%) and second highest in 
case of  men (72%). Saudi Arabia, a Middle Eastern coun-
try with a population around 23 million, has undergone 
significant economic and cultural changes over the past 
thirty years. Approximately 60% of  population are urban-
ized and have adopted lifestyle reflecting their physical 
activity and diet. The prevalence of  obesity has increased 
dramatically in Saudi Arabia and has reached epidemic 
proportions especially among females19. Obesity can be 
regarded as a major health problem among the Saudi pop-
ulation. A previous study indicated that in overall popu-
lation 13.05% males and 20.26%females were obese. The 
inter-relationship between obesity and insulin resistance; 
dyslipidemia and hypertension may contribute to cardio-
vascular risk; but the extent is not known20. Insulin affects 
mammalian lipid metabolism by stimulating synthesis of  
fatty acid in liver; adipose tissue and intestine. Since insu-
lin is also known to increase cholesterol synthesis. There-
fore, in the present study, liver, kidney, lipid, and thyroid 
profiles in addition to lactate dehydrogenase activity and 
fractionation of  its isoenzymes were evaluated in diabet-
ic, obese and obese diabetic patients as compared control 
normal subjects.
In this study, liver and kidney profiles were measured for 
the different groups and a significant increase in serum 
ALT activity in obese and obese diabetic patients was 
found. A number of  observational studies have suggest-
ed that abnormal liver function test is associated with 
obesity, insulin resistance, and metabolic syndromes21. 
Several prospective studies have also shown that high lev-
els of  ALT and GGT are independently associated with 
increased risk for incident metabolic syndrome and dia-
betes22. In non-diabetic subjects, some studies suggested 
that GGT might be a stronger predictor of  development 
of  type 2 diabetes than AST or ALT while others have 
suggested that ALT is the only predictor20.
Many studies have investigated the association of  in-
tramyocellular lipid stores as triglycerides with insulin 
resistance, showing either a positive correlation22 or no 
correlation23. In fact, no direct link has been established 
between insulin sensitivity and intramyocellular tri-
glycerides. The available studies on the intramyocellular 
triglycerides accumulation under different insulin-resis-
tance states (obesity and diabetes) have produced con-
troversial results. No difference in intramyocellular tri-
glycerides between diabetic subjects and body mass index 
(BMI)–matched controls. On the contrary it was report-
ed almost 2-fold higher levels of  intramyocellular tri-
glycerides in diabetic obese subjects compared with non-
diabetic obese subjects. There are some data indicating 
that intramyocellular lipids may be differentially regulated 
in diabetes and obesity. For example, diet-induced weight 
loss has resulted in a significant decrease in intramyocel-
lular triglycerides in diabetic obese subjects, but not in 
obese normoglycemic subjects24. 
Consequently, the role of  intramyocellular triglycerides in 
the pathophysiology of  diabetes remains unclear. Our re-
sults showed that triglycerides were increased significant-
ly in diabetic, obese and obese diabetic compared with 
control subjects, and also showed a highly significant in-
crease in obese and obese diabetic groups versus diabetic 
patients.
The influence of  other endocrine and non-endocrine or-
gans other than the pancreas on diabetes mellitus is doc-
umented. Occasionally other endocrine disorders such as 
abnormal thyroid hormones levels are found in diabetes25. 
The major alterations in thyroid hormones are a reduction 
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in the TSH stimulation of  the thyroid gland, probably 
caused by central hypothyroidism, and in the peripheral 
generation of  T3 from T4. In chemically induced diabetic 
animals, the alterations in the hypothalamo-pituitary-thy-
roid axis in diabetic rats are numerous; hypothalamic and 
plasma TRH, pituitary and plasma TSH, as well as TSH 
secretion rate are reduced, and the TSH response to TRH 
is decreased despite normal peripheral TSH metabolism. 
T3 and T4 production and iodide uptake by the thyroid 
are diminished.
There are also important structural changes in the thy-
roid and pituitary glands that are accompanied by marked 
alterations in their secretory activity. In addition, T4 de-
iodination to T3 in peripheral tissues is decreased. The 
physiological and biochemical inter-relationship between 
insulin and the influence of  both insulin and iodothy-
ronines on the metabolism of  carbohydrates, proteins 
and lipids are recorded26. Such records indicated that io-
dothyronines are insulin antagonist with high levels being 
diabetogenic while absence of  the hormone inhibits the 
development of  diabetes. The abnormal thyroid hor-
mones levels may be the outcome of  the various med-
ications the diabetics were receiving. For example, it is 
known that insulin; an anabolic hormone enhances the 
levels of  FT4 while it suppresses the levels of  T3 by in-
hibiting hepatic conversion of  T4 to T3. On the other 
hand, some of  the oral hypoglycemic agents such as the 
phenylthioureas are known to suppress the levels of  FT4 
and T4, while causing raised levels of  TSH26. In the cur-
rent study, we confirmed that the TSH was significantly 
increased in diabetic and obese diabetic as compared with 
control subjects and also increased in obese diabetic ver-
sus obese diabetic patients.
Lactate dehydrogenase (LDH) is an enzyme of  special 
interest due to its key position in anaerobic metabolic 
pathways. In the current study, LDH activities showed no 
significant change in diabetic and obese diabetic groups 
as compared with control subjects. Also, no significant 
change appeared in obese and obese diabetic as com-
pared with diabetic patients. In agreement with our study, 
Kamble et al.,27, found that mild diabetes mellitus has no 
effect on LDH, but raised plasma levels of  LDH in se-
vere diabetes mellitus was found to be highly significant 
which indicated the mild diabetic patients in our study.
In the present study, LDH isoenzymes activities showed 
different significant changes as compared with control 
and diabetic subjects. LDH 1, 2, 4 and 5 were significant-
ly decreased when compared with control and diabetic 
patients and LDH 3 was not significantly changed in the 
different compared groups. In contrast to our study, Vi-
zir28, showed that the shifts in the LDH activity proved 
to be characteristic of  all the degrees of  diabetes sever-
ity, and were expressed in a significant elevation of  total 
LDH, LDH4, 5 activities and a decrease of  LDH1, 2 ac-
tivities in comparison with healthy individuals. No change 
of  LDH3 activity was noted in mild forms of  diabetes. 
But in severe form the isoenzymatic spectrum was most-
ly changed on account of  LDH3 hyperfermentemia. In 
mild form of  diabetes, it approached control values.
Conclusion
Levels of  LDH isoenzymes were correlated with endo-
crine and biochemical parameters as TSH, FT4, ALT, tri-
glycerides and glucose in different studied groups. This 
will help to explore the changes associated with obesity 
and diabetes complication and to help in development of  
a management program to control complication of  these 
abnormalities.
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